Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million
Velan Capital sold 140,000 shares of Mineralys Therapeutics (MLYS), worth about $4.1 million, according to the report. Mineralys’ drug lorundrostat, an aldosterone synthase inhibitor for hypertension, is under FDA review for its first combination therapy application, with a decision expected by Dec. 22, 2026. Mineralys reported a $39.3 million Q1 loss and $646 million cash at March-end.
How this was made
The 30-second read
Why it matters
A specific FDA decision deadline is a key milestone for valuation in pre-revenue biotechs; however, the article does not introduce new trial efficacy/safety results, limiting immediate repricing catalysts.
Market read
Regulatory milestone framing for MLYS with a concrete decision timeline and stated cash runway; most actionable for milestone-traders rather than fundamental re-rating today.
What to watch
Cash runway (reported $646M at end of March) can reduce near-term financing risk, potentially supporting downside protection despite regulatory uncertainty.
Background
Lorundrostat (orally administered aldosterone synthase inhibitor) is being developed for uncontrolled/resistant hypertension; Mineralys is seeking FDA approval for use in combination with other antihypertensives.
Ticker impact
Mineralys Therapeutics’ lead drug lorundrostat is under FDA review, with a decision expected on or before Dec. 22, 2026.
Medium volatility into the FDA decision window; near-term trading likely dominated by biotech risk appetite rather than new trial data.
The article provides a concrete FDA decision deadline and notes ongoing cash runway, but no new efficacy/safety results.
Market effects
Highlights continued FDA review risk for aldosterone synthase inhibitor/hypertension drug development; may modestly affect sentiment for similar pre-revenue hypertension franchises.
Primarily US biotech sentiment; limited direct regional spillover beyond US-listed small/mid-cap healthcare risk.
FDA milestone underscores US regulatory gating for global hypertension programs; limited direct non-US impact without additional international filings.
Counterpoint
The stated decision date may already be known; without new clinical outcomes, the market may not materially reprice the stock.
Key entities
- companyMineralys Therapeutics
Pre-revenue biotech with lorundrostat under FDA review; expects an approval decision on or before Dec. 22, 2026.
- drug_candidateLorundrostat
Orally administered aldosterone synthase inhibitor for hypertension, reviewed by the FDA as a combination therapy.
- regulatorFood and Drug Administration (FDA)
Agency reviewing the first application for lorundrostat; decision expected by Dec. 22, 2026.
